BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36353537)

  • 1. Parthenolide and arsenic trioxide co-trigger autophagy-accompanied apoptosis in hepatocellular carcinoma cells.
    Yi J; Gong X; Yin XY; Wang L; Hou JX; Chen J; Xie B; Chen G; Wang LN; Wang XY; Wang DC; Wei HL
    Front Oncol; 2022; 12():988528. PubMed ID: 36353537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
    Wang W; Adachi M; Zhang R; Zhou J; Zhu D
    Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo.
    Song J; Zhao Z; Fan X; Chen M; Cheng X; Zhang D; Wu F; Ying X; Ji J
    Oncotarget; 2016 Oct; 7(43):70504-70515. PubMed ID: 27655700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
    Liu ZM; Tseng JT; Hong DY; Huang HS
    Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
    Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
    Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
    Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
    Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy.
    Sun J; Cheng M; Ye T; Li B; Wei Y; Zheng H; Zheng H; Zhou M; Piao JG; Li F
    Nanomedicine (Lond); 2022 Nov; 17(26):2037-2054. PubMed ID: 36789952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
    Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
    Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models.
    Huang A; Yue D; Liao D; Cheng L; Ma J; Wei Y; Tong A; Cheng P
    Oncol Rep; 2016 Dec; 36(6):3283-3290. PubMed ID: 27748945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZnAs@SiO
    Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
    Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
    [No Abstract]   [Full Text] [Related]  

  • 11. Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.
    Wang GZ; Zhang W; Fang ZT; Zhang W; Yang MJ; Yang GW; Li S; Zhu L; Wang LL; Zhang WS; Liu R; Qian S; Wang JH; Qu XD
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1125-36. PubMed ID: 24756364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
    Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D
    AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin.
    Chiu HW; Ho YS; Wang YJ
    J Mol Med (Berl); 2011 Sep; 89(9):927-41. PubMed ID: 21594580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
    Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
    Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
    Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
    Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression.
    Yang X; Sun D; Tian Y; Ling S; Wang L
    Tumour Biol; 2015 Apr; 36(4):2957-64. PubMed ID: 25492486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.
    Dong S; Li Z; Kong J; Wu S; Gao J; Sun W
    Int J Hyperthermia; 2022; 39(1):888-896. PubMed ID: 35848416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.
    Chen Y; Li H; Chen D; Jiang X; Wang W; Li D; Shan H
    Dig Dis Sci; 2022 Aug; 67(8):3806-3816. PubMed ID: 34383201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ETME, a novel β-elemene derivative, synergizes with arsenic trioxide in inducing apoptosis and cell cycle arrest in hepatocarcinoma cells via a p53-dependent pathway.
    Yu Z; Wu F; Chen L; Li Q; Wang C; Dong J; Xie SQ
    Acta Pharm Sin B; 2014 Dec; 4(6):424-9. PubMed ID: 26579413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
    Calviño E; Estañ MC; Simón GP; Sancho P; Boyano-Adánez Mdel C; de Blas E; Bréard J; Aller P
    Biochem Pharmacol; 2011 Dec; 82(11):1619-29. PubMed ID: 21889928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.